Law360| BioPharma Firm, Device Maker Blocked Generic, Sandoz Says

Teresa Bonder, Matthew Kent, Michael Kenny, and Andrew Hatchett are noted for representing Sandoz Inc. in an antitrust suit.

On November 4, Alston & Bird secured over $70 million in damages for client Sandoz in litigation against biopharmaceutical firm United Therapeutics Corp. (UTC). In 2019, Sandoz filed a suit alleging UTC blocked the sale of a generic version of hypertension medication by colluding with the manufacturer of infusion pumps for injecting UTC’s brand-name hypertension drug Remodulin to muscle out Sandoz’s generic alternative. Following a three-day bench trial, U.S. District Judge Brian R. Martinotti found Sandoz lost profits of $137.2 million and entered a judgment in favor of Sandoz, awarding damages of $61.6 million, plus prejudgment interest of $8.9 million, on its breach of contract claim against UTC. The win was featured in The American Lawyer’s Litigator of the Week, Law360’s Legal Lions column, and The New Jersey Law Journal.

Jenny Kramer is noted for representing Sandoz Inc. and Raregen LLC in an antitrust lawsuit before the U.S. District Court for the District of New Jersey.